Skip to content

Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients

The Relation Between Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06518473
Enrollment
100
Registered
2024-07-24
Start date
2024-07-14
Completion date
2025-12-15
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

atopy, frequency of exacerbation, chronic obstructive pulmonary disease

Brief summary

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. The presence of non-fully reversible airflow obstruction (FEV1/FVC \< 0.7 post-bronchodilation) measured by spirometry confirms the diagnosis of COPD

Detailed description

Chronic Obstructive Pulmonary Disease(COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. The presence of non-fully reversible airflow obstruction (FEV1/FVC \< 0.7 post-bronchodilation) measured by spirometry confirms the diagnosis of COPD Inflammation of the bronchial wall is characterized by the presence of neutrophils and macrophages and by increased concentrations of IL-8 and Th1 cytokines, as well as by a proteinase /antiproteinase imbalance, and this could explain the poorer response to inhaled corticosteroids (ICs) seen in COPD. Asthma may also be a risk factor for the development of chronic airflow obstruction and COPD and Epidemiological Study of Airway Obstructive Disease, adults diagnosed of asthma were found to have a 12-fold higher risk of acquiring COPD over time compared to those without asthma, after adjusting for smoking. Although both COPD and asthma are associated with chronic inflammation of the respiratory tract, there are differences in the inflammatory cells and mediators involved in the two diseases, some patients with COPD have an inflammatory pattern with increased eosinophils cells, similar to that of asthma. When there is diagnostic of Asthma and COPD overlap (ACO) uncertainty, an elevated total serum immunoglobulin E (IgE; \>100 international units/mL), elevated peripheral blood eosinophil count (\>300 cells/microL), and evidence of allergic disease (eg, skin testing or immunoassays for perennial allergen sensitivity) may point a clinician to asthma or Asthma - COPD overlap (ACO). Elevated sputum eosinophil counts, if available, are more common in asthma or ACO than COPD The Dutch hypothesis suggests that atopy and bronchial hyper-responsiveness , which are important markers of asthma, can be involved in the pathogenesis of COPD, although there is no clear evidence regarding the frequency of atopy (including asthma), Allergic rhinitis (AR), eczema, or increased IgE levels in patients with COPD, because most studies have involved small samples and limited evaluation of atopy.

Interventions

DIAGNOSTIC_TESTSkin prick test

Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold. Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)

Sponsors

Mansoura University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years

Inclusion criteria

* Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria

Exclusion criteria

* Patients with known allergic diseases before enrollment * Patients with associated other chronic respiratory disorders * Patients with significant comorbidities that could influence respiratory function. * Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Atopy in chronic obstructive pulmonary disease patients6 monthsTotal IgE (mg/dl) and ) will be assessed in chronic obstructive pulmonary disease patients
Chronic obstructive pulmonary disease patients2 monthsBlood eosinophil count (%) will be assessed in chronic obstructive pulmonary disease patients

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORMohamed AbdElmoniem, lecturer

Lecturer of chest medicine Faculty of medicine Mansoura university

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026